Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Praxis Precision Medicines Inc

Healthcare US PRAX

266.58USD
18.60(7.50%)

Last update at 2026-06-12T20:15:00Z

Day Range

247.26269.40
LowHigh

52 Week Range

12.4567.21
LowHigh

Fundamentals

  • Previous Close 247.98
  • Market Cap773.45M
  • Volume423159
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-129.73000M
  • Revenue TTM2.19M
  • Revenue Per Share TTM0.24
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-11.27

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -214.02900M -167.06100M -61.82800M -35.59600M -26.40200M
Minority interest - - - - -
Net income -213.07200M -166.87900M -61.82000M -35.51200M -26.53500M
Selling general administrative 59.95M 47.08M 16.99M 6.23M 3.90M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.42M 0.18M 0.05M 0.04M 0.00100M
Ebit -215.40500M -167.51400M -62.01800M -35.78900M -26.27500M
Ebitda -214.98600M -167.33200M -61.96800M -35.55900M -26.27400M
Depreciation and amortization 0.42M 0.18M 0.05M 0.23M 0.00100M
Non operating income net other 0.96M 0.27M 0.14M - -
Operating income -214.98600M -167.33200M -61.96800M -35.78900M -22.71900M
Other operating expenses 214.99M 167.33M 61.97M 35.79M 22.72M
Interest expense 0.42M 0.18M 0.19M 0.00000M 0.13M
Tax provision 0.00000M 0.00000M -0.00800M -0.08400M 0.13M
Interest income - - 0.14M 0.19M 0.09M
Net interest income - - 0.14M 0.19M -0.03500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.95700M -0.18200M -0.00800M -0.08400M 0.13M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 214.99M 167.33M 61.97M 35.79M 22.72M
Cost of revenue - - - - -
Total other income expense net 0.96M 0.27M 0.14M 0.19M -3.64800M
Discontinued operations - - - - -
Net income from continuing ops -214.02900M -167.06100M -61.82000M -35.51200M -26.53500M
Net income applicable to common shares -214.02900M -167.06100M -70.32300M -40.68200M -29.22300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 87.95M 115.13M 292.75M 303.18M 47.69M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.58M 10.35M 11.50M 5.72M 0.68M
Total liab 18.28M 39.02M 41.94M 15.72M 7.58M
Total stockholder equity 69.67M 76.11M 250.81M 287.46M 40.11M
Deferred long term liab - - - - -
Other current liab 7.42M 14.85M 22.53M 10.87M 3.46M
Common stock 0.01M 0.00500M 0.00500M 0.00400M 0.00100M
Capital stock 0.01M 0.00500M 0.00500M 0.00400M 0.00100M
Retained earnings -653.92100M -530.64400M -316.61500M -149.55400M -81.00900M
Other liab - 2.18M - - -
Good will - - - - -
Other assets - 0.42M 0.47M 0.77M 0.62M
Cash 81.30M 61.62M 138.70M 296.61M 44.81M
Cash and equivalents - - - - -
Total current liabilities 15.75M 35.52M 37.62M 15.72M 6.82M
Current deferred revenue 1.39M 5.00M - - -
Net debt -78.80500M -57.11000M -134.39300M -295.84500M -43.35600M
Short term debt 1.13M 1.00M 4.31M 0.76M 0.70M
Short long term debt - - - - -
Short long term debt total 2.50M 4.50M 4.31M 0.76M 1.46M
Other stockholder equity 723.58M 606.92M 567.60M 437.01M -121.08300M
Property plant equipment - 0.97M 4.87M 0.84M 1.58M
Total current assets 84.88M 110.84M 287.41M 302.33M 45.50M
Long term investments - - - - -
Net tangible assets - 76.11M 250.81M 287.46M -81.00800M
Short term investments 0.00000M 38.87M 137.21M - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 5.82M 14.67M 10.78M 4.09M 2.67M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -0.17300M -0.17600M -303.17700M -0.03800M
Additional paid in capital - - - - -
Common stock total equity - 0.00500M 0.00500M 0.00400M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -530.64400M -316.61500M -149.55400M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.42M 0.42M 0.47M 0.01M 0.62M
Deferred long term asset charges - - - - -
Non current assets total 3.07M 4.29M 5.34M 0.85M 2.20M
Capital lease obligations 2.50M 3.50M 4.31M 0.76M 1.46M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 97.33M -139.47000M -139.47000M -0.10300M -0.06300M
Change to liabilities -6.57300M 7.27M 0.96M -0.83700M 1.67M
Total cashflows from investing activities 96.89M -140.52000M 0.00400M -0.10300M -0.06300M
Net borrowings - - - - 1.00M
Total cash from financing activities 10.46M 107.59M 304.42M 60.39M 37.80M
Change to operating activities -10.67300M 8.87M 2.28M 1.58M -0.20800M
Net income -214.02900M -167.06100M -61.82000M -35.51200M -26.53500M
Change in cash -77.68900M -157.48800M 251.79M 26.86M 17.02M
Begin period cash flow 139.72M 297.21M 45.41M 18.55M 1.53M
End period cash flow 62.03M 139.72M 297.21M 45.41M 18.55M
Total cash from operating activities -185.04300M -124.55400M -52.62300M -33.42000M -20.72100M
Issuance of capital stock 9.56M 105.71M 334.33M 60.39M 36.80M
Depreciation 0.42M 0.18M 0.05M 0.04M 0.00100M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 1.16M 100.86M -30.00000M - -
Other cashflows from financing activities 0.90M 1.87M 133.53M -0.10300M 37.80M
Change to netincome 28.65M 26.19M 5.91M 1.31M 4.35M
Capital expenditures 0.44M 1.05M 0.00400M 0.10M 0.06M
Change receivables - - - - -
Cash flows other operating 5.49M -5.13100M -4.43200M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -77.68900M -157.48800M 251.80M - -
Change in working capital -1.78100M 16.13M 3.24M 0.74M 1.46M
Stock based compensation 28.59M 22.69M 5.21M 0.67M 0.58M
Other non cash items 1.75M 1.41M 0.70M 0.64M 0.13M
Free cash flow -185.48700M -125.60400M -52.61900M -33.52300M -20.78400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRAX
Praxis Precision Medicines Inc		 18.60 7.50% 266.58 - - 385.19 13.53 352.99 -6.8585
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Inc

99 High Street, Boston, MA, United States, 02110

Key Executives

Name Title Year Born
Mr. Marcio Souza M.B.A. Pres, CEO & Director 1980
Ms. Nicole Sweeny Chief Commercial Officer 1975
Dr. Steven Petrou B.Sc. (Hons.), Ph.D. Co-Founder & Chief Scientific Officer NA
Mr. Timothy Edwin Kelly CFO & Treasurer 1973
Lauren Mastrocola VP of Fin. & Principal Accounting Officer NA
Dr. Karl Hansen Ph.D. Chief Technical Operations Officer NA
Alex Kane VP of Investor Relations & Corp. Communications NA
Mr. Alex Nemiroff J.D. Gen. Counsel & Sec. 1979
Ms. Kelly McCue Chief People Officer NA
Ms. Alyssa J. S. Wyant Chief Regulatory & Quality Officer 1975

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.